Guardian Pharmacy Services (GRDN) Earnings Analysis
Guardian Pharmacy Services (GRDN) next reports earnings on 2026-08-06, consensus EPS 0.26 USD. Last quarter (2026-03-11) it beat with EPS 0.37 USD vs 0.27 USD est (+37%). It has beaten estimates in 3/4 recent quarters (75%). Trailing P/E 46.79.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does GRDN next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | 0.26 USD |
| Revenue estimate | 0.34B |
GRDN earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-11 | 0.37 USD | 0.27 USD | +37% | Beat |
| 2025-11-10 | 0.25 USD | 0.24 USD | +4.2% | Beat |
| 2025-08-11 | 0.23 USD | 0.22 USD | +4.5% | Beat |
| 2025-05-12 | 0.21 USD | 0.22 USD | -4.5% | Miss |
| 2024-08-22 | 0.245 USD | n/a | n/a | n/a |
Beat rate: 3/4 (75%) over reported quarters with consensus data.
GRDN valuation and analyst view
| Trailing P/E | 46.79 |
|---|---|
| Trailing EPS | 0.83805 USD |
| Price / book | 11.40 |
| Dividend yield | 0.00% |
| Market cap | 2.52B |
| Analyst consensus | Buy (4 buy / 0 hold / 0 sell) |
| Avg price target | 47 USD |
Related research pages
Frequently asked questions
When is Guardian Pharmacy Services (GRDN)'s next earnings date?
Guardian Pharmacy Services is next scheduled to report on 2026-08-06, with a consensus EPS estimate of 0.26 USD and revenue estimate of 0.34B.
Did GRDN beat earnings last quarter?
In its 2026-03-11 report, GRDN posted EPS of 0.37 USD versus a 0.27 USD estimate — a beat of 37%.
What is GRDN's earnings track record?
Over the last 4 reported quarters with consensus data, GRDN beat estimates 3 times (75%).
What is GRDN's current P/E ratio and EPS?
GRDN trades at a trailing P/E of 46.79 on trailing EPS of 0.8380474092323242 USD.
What do analysts rate GRDN?
Analyst consensus is "Buy" across 4 ratings (0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 47 USD.